FDA Discovers Microbial Contamination in Compound Pharmacy Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Discovers Microbial Contamination in Compound Pharmacy Products


FDA has identified bacterial and fungal growth in samples from two unopened vials from two separate lots of preservative-free (PF) methylprednisolone acetate (MPA) 80 mg/mL, 10mL vials during investigation of Main Street Family Pharmacy of Newbern, TN. The agency is still evaluating additional samples and lots of PF MPA, as well as other sterile products produced by Main Street. FDA, in partnership with CDC, is working to identify the exact species of fungus and bacteria observed in the vials.

While FDA has received reports of adverse events, including skin and soft tissue abscesses, the agency stated on its website that it is “not aware of any cases of meningitis associated with Main Street’s preservative free methylprednisolone acetate for injection.” FDA, however, recommends that patients discontinue use of the products. Main Street issued a voluntary nationwide recall of all lots of all sterile products compounded by the company on May 28, 2013.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here